Project description
Opening the door to personalised medicine for dementia
Personalised medicine takes into account individual variability and unique characteristics such as a person’s genetic makeup, biomarkers, and personal health data to provide tailored treatment and preventive strategies. Although personalised medicine holds great potential, the lack of appropriate tools has impeded its implementation. Funded by the HORIZON programme, the PROMINENT project aims to develop a digital platform for precision medicine, addressing barriers in utilising advanced diagnostics and disease-modifying therapies. The platform will encompass prediction models that rely on various diagnostic data sources and it will focus on neurodegenerative disorders which are increasing in prevalence due to the ageing population. The expected outcomes include enhanced diagnostic precision, improved application of new treatment options, and improved health outcomes.
Objective
Neurodegenerative diseases are one of the most important contributors to morbidity and mortality in the elderly. In Europe, over 14 million people are currently living with dementia, at a cost of over 400 billion EUR annually. Comorbidities with these conditions are frequent and a major obstacle to optimal diagnosis and management. Recent advances in diagnostic technologies and the advent of disease-modifying therapies (DMT) for Alzheimer’s disease (AD), the most common aetiology of dementia, heralds the beginning of precision medicine in this disease area. PROMINENT will develop a digital platform for precision medicine that will remove barriers that currently exists for leveraging these technological advancements in the routine care of patients with neurodegenerative disorders and co-morbidities. The platform gives clinicians access to prediction models leveraging multimodal diagnostic data automatically derived from multiple sources (imaging repositories, medical records, mobile devices), helping them choose optimal care pathways and improving diagnostic precision. It will provide personalized, relevant and meaningful information on diagnosis and prognosis in a format understandable by patients and care partners. Further, it will support the introduction of new health technologies such as DMT for AD, by ensuring adherence to appropriate use guidelines and facilitating the prospective collection of data on real-world usage, safety and effectiveness. The expected impact of the project is to increase diagnostic accuracy and optimized use of existing and new treatment options. It will empower patients and caregivers by engaging them in more person-centric health care decisions, leading to improved adherence and patient experience. Ultimately this is expected to lead to cost-effective care, improved health outcomes and quality of life.
Fields of science
Programme(s)
- HORIZON.2.1 - Health Main Programme
- HORIZON.2.1.7 - Innovative Health Initiative
Funding Scheme
HORIZON-JU-RIA - HORIZON JU Research and Innovation ActionsCoordinator
17177 Stockholm
Sweden